Mallinckrodt and Palatin sign LeuTech agreement:
This article was originally published in Clinica
Palatin's first commercial product, LeuTech, will be licensed to Mallinckrodt. Saint Louis, Missouri-based Mallinckrodt will pay Princeton, New Jersey-based Palatin a $500,000 licensing fee and buy 700,000 Palatin shares for a total of $13 million. LeuTech is a radiolabelled monoclonal antibody for diagnosing infections. It is injected into a vein and a gamma camera locates the agglomeration of white cells at the infection site. The initial indication is for equivocal cases of appendicitis.
You may also be interested in...
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.